Allostery and Biased Agonism at Class B G Protein-Coupled Receptors

Research output: Contribution to journalReview ArticleResearchpeer-review

Abstract

Class B G protein-coupled receptors (GPCRs) respond to paracrine or endocrine peptide hormones involved in control of bone homeostasis, glucose regulation, satiety, and gastro-intestinal function, as well as pain transmission. These receptors are targets for existing drugs that treat osteoporosis, hypercalcaemia, Paget's disease, type II diabetes, and obesity and are being actively pursued as targets for numerous other diseases. Exploitation of class B receptors has been limited by difficulties with small molecule drug discovery and development and an under appreciation of factors governing optimal therapeutic efficacy. Recently, there has been increasing awareness of novel attributes of GPCR function that offer new opportunity for drug development. These include the presence of allosteric binding sites on the receptor that can be exploited as drug binding pockets and the ability of individual drugs to enrich subpopulations of receptor conformations to selectively control signaling, a phenomenon termed biased agonism. In this review, current knowledge of biased signaling and small molecule allostery within class B GPCRs is discussed, highlighting areas that have progressed significantly over the past decade, in addition to those that remain largely unexplored with respect to these phenomena.

Original languageEnglish
Pages (from-to)111-138
Number of pages28
JournalChemical Reviews
Volume117
Issue number1
DOIs
Publication statusPublished - 11 Jan 2017

Cite this

@article{7d64b7f867b04a319e8e6b623f976714,
title = "Allostery and Biased Agonism at Class B G Protein-Coupled Receptors",
abstract = "Class B G protein-coupled receptors (GPCRs) respond to paracrine or endocrine peptide hormones involved in control of bone homeostasis, glucose regulation, satiety, and gastro-intestinal function, as well as pain transmission. These receptors are targets for existing drugs that treat osteoporosis, hypercalcaemia, Paget's disease, type II diabetes, and obesity and are being actively pursued as targets for numerous other diseases. Exploitation of class B receptors has been limited by difficulties with small molecule drug discovery and development and an under appreciation of factors governing optimal therapeutic efficacy. Recently, there has been increasing awareness of novel attributes of GPCR function that offer new opportunity for drug development. These include the presence of allosteric binding sites on the receptor that can be exploited as drug binding pockets and the ability of individual drugs to enrich subpopulations of receptor conformations to selectively control signaling, a phenomenon termed biased agonism. In this review, current knowledge of biased signaling and small molecule allostery within class B GPCRs is discussed, highlighting areas that have progressed significantly over the past decade, in addition to those that remain largely unexplored with respect to these phenomena.",
author = "Denise Wootten and Miller, {Laurence J.} and Cassandra Koole and Arthur Christopoulos and Sexton, {Patrick M.}",
year = "2017",
month = "1",
day = "11",
doi = "10.1021/acs.chemrev.6b00049",
language = "English",
volume = "117",
pages = "111--138",
journal = "Chemical Reviews",
issn = "0009-2665",
publisher = "American Chemical Society",
number = "1",

}

Allostery and Biased Agonism at Class B G Protein-Coupled Receptors. / Wootten, Denise; Miller, Laurence J.; Koole, Cassandra; Christopoulos, Arthur; Sexton, Patrick M.

In: Chemical Reviews, Vol. 117, No. 1, 11.01.2017, p. 111-138.

Research output: Contribution to journalReview ArticleResearchpeer-review

TY - JOUR

T1 - Allostery and Biased Agonism at Class B G Protein-Coupled Receptors

AU - Wootten, Denise

AU - Miller, Laurence J.

AU - Koole, Cassandra

AU - Christopoulos, Arthur

AU - Sexton, Patrick M.

PY - 2017/1/11

Y1 - 2017/1/11

N2 - Class B G protein-coupled receptors (GPCRs) respond to paracrine or endocrine peptide hormones involved in control of bone homeostasis, glucose regulation, satiety, and gastro-intestinal function, as well as pain transmission. These receptors are targets for existing drugs that treat osteoporosis, hypercalcaemia, Paget's disease, type II diabetes, and obesity and are being actively pursued as targets for numerous other diseases. Exploitation of class B receptors has been limited by difficulties with small molecule drug discovery and development and an under appreciation of factors governing optimal therapeutic efficacy. Recently, there has been increasing awareness of novel attributes of GPCR function that offer new opportunity for drug development. These include the presence of allosteric binding sites on the receptor that can be exploited as drug binding pockets and the ability of individual drugs to enrich subpopulations of receptor conformations to selectively control signaling, a phenomenon termed biased agonism. In this review, current knowledge of biased signaling and small molecule allostery within class B GPCRs is discussed, highlighting areas that have progressed significantly over the past decade, in addition to those that remain largely unexplored with respect to these phenomena.

AB - Class B G protein-coupled receptors (GPCRs) respond to paracrine or endocrine peptide hormones involved in control of bone homeostasis, glucose regulation, satiety, and gastro-intestinal function, as well as pain transmission. These receptors are targets for existing drugs that treat osteoporosis, hypercalcaemia, Paget's disease, type II diabetes, and obesity and are being actively pursued as targets for numerous other diseases. Exploitation of class B receptors has been limited by difficulties with small molecule drug discovery and development and an under appreciation of factors governing optimal therapeutic efficacy. Recently, there has been increasing awareness of novel attributes of GPCR function that offer new opportunity for drug development. These include the presence of allosteric binding sites on the receptor that can be exploited as drug binding pockets and the ability of individual drugs to enrich subpopulations of receptor conformations to selectively control signaling, a phenomenon termed biased agonism. In this review, current knowledge of biased signaling and small molecule allostery within class B GPCRs is discussed, highlighting areas that have progressed significantly over the past decade, in addition to those that remain largely unexplored with respect to these phenomena.

UR - http://www.scopus.com/inward/record.url?scp=85018235637&partnerID=8YFLogxK

U2 - 10.1021/acs.chemrev.6b00049

DO - 10.1021/acs.chemrev.6b00049

M3 - Review Article

VL - 117

SP - 111

EP - 138

JO - Chemical Reviews

JF - Chemical Reviews

SN - 0009-2665

IS - 1

ER -